The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S. Ryoncil is the only MSC therapy ...

The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft ...

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

For patients with haploidentical hematopoietic cell transplantation (haplo-HCT), the addition of itacitinib to standard graft ...

FDA approves Mesoblast's Ryoncil, the first U.S. MSC therapy, for children with steroid-refractory acute graft-versus-host disease. In a Phase 3 trial, 70% of SR-aGvHD patients responded to ...

For patients with haploidentical hematopoietic cell transplantation (haplo-HCT), the addition of itacitinib to standard graft versus host disease (GvHD) prophylaxis is well tolerated and results ...

Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...